Menstrual Migraine - An opportunity to gain a competitive advantage for triptan manufacturers

Introduction

Menstrual migraine affects over 15 million women across the seven major pharmaceutical markets. At present the disease is managed using a wide variety of pharmacological treatments. However, none of these compounds have an indication specifically for menstrual migraine. With the market relatively untapped, it presents an abundance of commercial opportunities for pharmaceutical manufacturers. 

Scope

Overview of epidemiology data and patient potential of the menstrual migraine market 

Evaluation of current treatments and key unmet needs 

Therapeutic and market potential of compounds in clinical trials 

Commercial opportunities for compounds currently being used off-label 

Report Highlights

Pharmaceutical manufacturers competing in the migraine market should adopt the standardized definition of menstrual migraine proposed by the International Headache Society. 

Research and development should focus on compounds that address unmet needs such as migraine specific compounds, short-term prophylactic therapies, treatment refractory patients, and quicker onset of action.  

Extensive placebo-controlled trials should be initiated to provide robust data showing the true clinical advantages of medications ( i.e. triptans) for menstrual migraine. Other drug manufacturers with anticonvulsant and antidepressant therapies should position their products as an alternative treatment for menstrual migraine. 

Reasons to Purchase

Assess the patient potential of the menstrual migraine market 

Identify the level of unmet need and subsequent market opportunities 

Evaluate the therapeutic potential of compounds in clinical trials 

Publisher: Datamonitor CNS Central Nervous System Reports 

To order go to this URL: http://www.bioportfolio.com/cgi-bin/acatalog/Datamonitor_CNS.html#a99